Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:1
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [11] Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer
    Kramer, M. W.
    Gakis, G.
    UROLOGE, 2020, 59 (07): : 784 - 789
  • [12] Immune Therapies in Non-Muscle Invasive Bladder Cancer
    Ho, Philip L.
    Williams, Stephen B.
    Kamat, Ashish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (02)
  • [13] Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review
    Mcnall, Shannon
    Hooper, Kailey
    Sullivan, Travis
    Rieger-Christ, Kimberly
    Clements, Matthew
    CANCERS, 2024, 16 (10)
  • [14] Role of Tissue Markers on Predicting the Prognosis of Intermediate and High-risk Non-muscle Invasive Bladder Cancer
    Abbasli, Abulfaz
    Citgez, Sinharib
    Demirdag, Cetin
    Gurbuz, Ahmet
    Erozenci, Ahmet
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2020, 19 (04): : 177 - 181
  • [15] PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG
    de Jong, Florus C.
    Kvikstad, Vebjorn
    Hoedemaeker, Robert F.
    van der Made, Angelique C. J.
    van der Bosch, Thierry P.
    van Casteren, Niels J.
    van Kessel, Kim E. M.
    Zwarthoff, Ellen C.
    Boormans, Joost L.
    Zuiverloon, Tahlita C. M.
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [16] ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
    Monteiro, Leonardo L.
    Witjes, J. Alfred
    Agarwal, Piyush K.
    Anderson, Christopher B.
    Bivalacqua, Trinity J.
    Bochner, Bernard H.
    Boormans, Joost L.
    Chang, Sam S.
    Dominguez-Escrig, Jose L.
    McKiernan, James M.
    Dinney, Colin
    Godoy, Guilherme
    Kulkarni, Girish S.
    Mariappan, Paramananthan
    O'Donnell, Michael A.
    Rentsch, Cyrill A.
    Shah, Jay B.
    Solsona, Eduardo
    Svatek, Robert S.
    van der Heijden, Antoine G.
    van Valenberg, F. Johannes P.
    Kassouf, Wassim
    WORLD JOURNAL OF UROLOGY, 2019, 37 (01) : 51 - 60
  • [17] Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer
    Soltani-Tehrani, Amir M.
    Kumar, Aman
    Pohar, Kamal S.
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6489 - 6502
  • [18] Guideline-based management of non-muscle invasive bladder cancer
    Gregg, Justin R.
    Dahm, Philipp
    Chang, Sam S.
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 320 - 326
  • [19] High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care
    Palkowski, Thomas
    Bibeau, Frederic
    Thiery-Vuillemin, Antoine
    Kleinclauss, Francois
    Frontczak, Alexandre
    FRENCH JOURNAL OF UROLOGY, 2025, 35 (03):
  • [20] Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
    Roman Mayr
    Maximilian Burger
    Current Urology Reports, 2013, 14 : 90 - 93